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Maintenance of telomeres – specialized complexes that protect the ends of chromosomes – is provided by
the enzyme complex telomerase, which is a key factor that is activated inmore than 80% of cancer cells, but
absent in most normal cells. Targeting telomere maintenance mechanisms could potentially halt tumour
growth across a broad spectrum of cancer types. Telomeric ends of chromosomes consist of noncoding
repeat sequences of guanine-rich DNA. These G-rich ends can fold into structures called G-
quadruplexes. Stabilization of G-quadruplexes by small binding molecules called G4 ligands can prevent
telomerase enzyme from maintaining telomere integrity in cancer cells. G-quadruplexes can exist in
other parts of the genome too, especially within promoter sequences of oncogenes, and also be
interesting drug targets. Here, we describe the development of a new series of novel bis-triazoles,
designed to stabilize G-quadruplex structures selectively as G4 ligands. FRET assays showed two
compounds to be moderately eﬀective G4 binders, with particular aﬃnity for the quadruplex formed by
the Hsp90a promoter sequence, and good selectivity for G-quadruplex DNA vs. duplex DNA. However,
CD spectroscopy failed to provide any information about the folding topology of the human telomeric
G-quadruplex resulting from its interaction with one of the ligands. All the new ligands showed potent
cell growth inhibitory properties against human colon and pancreatic cancer cell lines, as evidenced by
the MTT assay; notably, they were more potent against cancer cells than in fetal lung ﬁbroblasts.
Docking studies were performed to rationalize the aﬃnity of these ligands for binding to the telomeric
parallel G-quadruplex DNA.Introduction
In eukaryotes, the ends of chromosomes are protected by telo-
meres, the specialized protein–DNA complexes that prevent
end-to-end fusions, recombination and damage to the genome.1
In humans, telomeres consist of the sequence (50-GGGTTA-30),
which is referred to as the “telomeric repeat”.2 These repeating
sequences are predominantly double-stranded. However there
is an overhanging single-stranded G-rich 30-end, known as 30-
overhang or G-strand, which plays an important structural and
functional role.3 Each chromosome end contains approximately
1000 to 2000 telomeric repeats.2 In human somatic cells, telo-
mere length decreases with each cell division event until it
reaches a critical level, at which point cell division ceases, pre-
venting loss of vital chromosomal genetic information.4,5lar Science, University of Nottingham,
ham, University Park, Nottingham NG7
.uk
Alia Airport Road, Amman 11 622, UK
ESI) available: Chemistry experimental
LC-MS data for the tested compounds
nds 34–53. See DOI: 10.1039/c7ra07257k
hemistry 2017Telomeres are replenished by an enzyme called telomerase,
a “ribonucleoprotein complex” that functions as a reverse tran-
scriptase to add multiple copies of (50-GGGTTA-30) – in all verte-
brates – to the end of the G-strand of the telomere. Human
telomerase consists of two main components: a protein called
hTERT (human telomerase reverse transcriptase) and an RNA (30-
CAAUCCCAAUC-50) known as hTR (human telomerase RNA) or
hTERC (human telomerase RNA component). The protein hTERT
uses hTERC to add a six-nucleotide repeating sequence (50-
GGGTTA-30) to the 30 G-strand of chromosomes.6,7 A number of
studies has revealed that telomerase activity is almost absent in
normal somatic cells. However, a low level of telomerase activity
has been discovered in mitotically active cells, including skin,
lymphocytes, and endometrium because telomerase activity in
these proliferating cells is regulated by growth. But in >80%
cancers, tumour cells possess short telomeres and high levels of
telomerase activity.3 For this reason, most telomere-related anti-
tumour strategies target the telomerase enzyme by which telo-
mere maintenance is provided; the inhibition of telomerase
activity results in the reduction of telomere length, and ultimately
delayed cell death and abrogation of tumorigenicity in vivo.6
The telomeric DNA G-strand folds to form G-quadruplexes,
also known as G4-DNA, which are four stranded structuresRSC Adv., 2017, 7, 47297–47308 | 47297
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View Article Onlineformed by nucleic acid sequences which are rich in guanine
(Fig. 1). Each structure contains several stacked square
arrangements of guanines called G-quartets.8 Each G-quartet is
composed of four guanines held together by a cyclic arrange-
ment of eight hydrogen bonds. The presence of a central
monovalent cation (typically potassium) helps to maintain the
stability of the structure.6,9,10
Two principal categories of G-quadruplex nucleic acids have
received attention as potential therapeutic targets: (i) those
capable of being formed at the single-stranded G-overhang of
telomeric DNA, for which appropriate small molecule ligands can
induce G-quadruplex formation, stabilize its structure, inhibit
telomerase activity and telomere elongation, and selectively
target telomere maintenance, (ii) those within genomes, espe-
cially within promoter sequences of genes involved in cellular
proliferation and oncogenes such as c-myc, c-kit, and Hsp90. It
has been suggested that ligands that bind selectively with
promoter G-quadruplexes could in principle down-regulate the
expression of these genes and thus have an anticancer eﬀect.11,12
The G-quadruplex stabilization occurs, in most cases, via p–p
staking and electronic interactions resulting in binding of the
ligand on the G-quartet of the external face of the G-quadruplex
(external stacking).13 A wide range of small molecules such
as BRACO-19,14 telomestatin,15 RHPS4,16 MMQ3,17 Mn(III)-
porphyrin,18 BMSG-SH-3,12 and TRZ,1,19 have been investigated as
G-quadruplex binding and stabilizing ligands (Fig. 2).Fig. 1 Left: structure of a G-quartet involving four coplanar guanines
intramolecular G-quadruplex. Blue and red boxes represent guanine base
T. Ishizuka, K. Kurabayashi, M. Komiyama, Angew. Chem., Int. Ed. 2009
Reproduced with permission. And L.-P. Bai, M. Hagihara, K. Nakatani, Z.-H
with permission from Nature Publishing Group.
47298 | RSC Adv., 2017, 7, 47297–47308An eﬃcient G-quadruplex ligand should feature; (i) a large
aromatic at surface, much larger than that of a duplex binder
to improve the aromatic–aromatic overlap and provide selec-
tivity, (ii) short alkyl chain substituents normally terminating in
an amino group that is fully cationic at physiological pH. The
positively charged amino groups improve the water-solubility of
the ligand and create electrostatic interactions between the
ligand and the G-quadruplex–DNA scaﬀold.11,13
We report here the design, synthesis, biophysical and bio-
logical evaluations, and molecular modeling studies of a new
series of bis-triazoles, based upon a benzo[2,3-d, 5,6-d]
ditriazolo-4,8-dione scaﬀold, which were developed to stabi-
lize G-quadruplex structures selectively, as G4 ligands and
experimental antitumour agents. We selected this scaﬀold for
a number of reasons: rstly it features a novel planar G-
quadruplex stacking moiety; secondly synthetic routes to the
nal compounds are highly convergent, quick, and exible; and
thirdly the symmetrical nature of the ligands potentially
simplies the analysis of their interactions with DNA.
Results and discussion
Synthetic chemistry
A new series of bis-triazoles were designed to display both
hydrophobic and hydrophilic characteristics to bind to and
stabilize G-quadruplex structures, as G4 ligands. The designwith a central monovalent cation (guanine arrangement). Right: an
s in the anti and syn conformations, respectively.6 Adapted from Y. Xu,
, 48, 7833–7836. Copyright Wiley-VCH Verlag GmbH & Co. KGaA.9
. Jiang, Nature Sci. Rep. DOI: 10.1038/srep06767, 2014.10 Reproduced
This journal is © The Royal Society of Chemistry 2017
Fig. 2 Examples of G-quadruplex binding and stabilizing ligands reported in the literature.
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View Article Onlineincluded an aromatic core, represented by the bis-(benzyl-
triazolo)benzoquinone moiety, that promotes p-stacking with
the G4 platform, and two protonatable side arms (amino
groups) around the aromatic core. The positively charged amino
groups are expected to improve the hydrophilicity of the ligands
and create electrostatic interactions with the G4-grooves.
The synthesis of the hydrophobic aromatic core required
a three-step process, as shown in Scheme 1. Heating the
commercially available p-nitrobenzyl bromide 1 with sodium
azide aﬀorded p-nitrobenzyl azide 2 in yields of 82%.20 1,3-
Dipolar cycloaddition reaction of 2 with benzoquinone 3 in the
ratio 2 : 1 under reux condition in ethyl acetate yielded 66% of
bis-triazole 4.21–23 Bis-triazole core 5 was obtained in good yield
(92%) by palladium catalyzed hydrogenation of 4 with
hydrogen. 13C NMR spectra for bis-triazoles 4 and 5 showed one
peak for one carbonyl carbon which conrmed the symmetricalThis journal is © The Royal Society of Chemistry 2017trans-regioisomer rather than cis-isomer that would show two
diﬀerent carbonyl signals.
A three-step route was followed to obtain the side chains 24–
33 (Scheme 2). The halo esters 6a–d were heated with secondary
amines (diethylamine, morpholine and piperidine) to give the
corresponding amino esters 7–13 in yields of 55–94%,24 while
the morpholine derivative 10 was commercially available.
Conversion into the corresponding amino acids 14–23 was
achieved by treating esters 7–13 with potassium hydroxide.
Acids 14, 19 and 20 were available commercially. Treating acids
14–23 with oxalyl chloride and a catalytic amount of DMF under
an inert atmosphere produced the side chain acid chlorides 24–
33, which were used immediately for the next step.
The acid chlorides 24–33 were coupled successively to the
hydrophobic aromatic core 5 in the presence of pyridine as
a catalyst and under inert atmosphere to give novel compoundsRSC Adv., 2017, 7, 47297–47308 | 47299
Scheme 1 Synthetic route for the aromatic core of bis-triazole 5. Reagents and conditions: (i) NaN3, acetone, reﬂux, 24 h, 82%; (ii) ethyl acetate,
reﬂux, 48 h, 66%; (iii) H2, Pd/C, DMF, rt, 4 h, 93%.
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View Article Online34–43 in yields of 38–90%. Treating amines 34–43 with
hydrogen chloride in methanol solution, converted them into
the corresponding hydrochloride salts 44–53 in good yields
(65–95%), as shown in Scheme 3. The salts were puried either
by trituration in hot methanol or recrystallization from meth-
anol–light petroleum (1 : 1).
A mechanism is proposed in Scheme 4 for the formation of
bis-triazole 4. The rst step is the 1,3-dipolar cycloaddition
reaction of azide 2 with the activated C]C of p-benzoquinone 3
to produce the mono-triazoline intermediate A which is tauto-
merized and oxidized by the excess of 3 to form the mono-
triazole adduct C derivative. A second 1,3-dipolar cycloaddi-
tion reaction and oxidation takes place in the same way to
produce the trans-bis-triazole 4.21,22 The TLC analysis of the
reaction mixture ltrates indicted the presence of excess
organic azides and large amounts of hydroquinone whichScheme 2 General synthetic route for side chains 24–33. Reagents an
ethanol or methanol, rt, 3–6 h, (b) 0.25 M HCl; (iii) oxalyl chloride, DMF,
47300 | RSC Adv., 2017, 7, 47297–47308supports the proposal that excess benzoquinone plays the role
of the required oxidant.Binding to DNA
1. FRET assay. Bis-triazoles 44–53 were evaluated for
their ability to bind and stabilize G-quadruplex DNA selec-
tively by a FRET melting assay.25–27 Four labeled oligomers
were used: F21T is a G-quadruplex forming oligomer of the
human telomeric sequence (50-FAM-GGGTTAGGGTTAGGGT-
TAGGG-TAMRA-30), c-kit2 is a G-quadruplex forming oligomer
of c-kit2 oncogene (50-FAM-CCCGGGCGGGCGCGAGG-
GAGGGGAGG-TAMRA-30), Hsp90a is G-quadruplex forming
oligomer of the promoter sequence of Hsp90a (50-FAM-
GGGCCAAAGGGAAGGGGTGGG-TAMRA-30), and F10T (ds)
is a hairpin double helix forming labelled oligomerd conditions: (i) acetonitrile, reﬂux, 2–8 h, 55–94%; (ii) (a) KOH, H2O/
CH2Cl2, rt, 2–20 h.
This journal is © The Royal Society of Chemistry 2017
Scheme 3 General synthetic route for the target ligands 44–53.
Reagents and conditions: (i) (a) pyridine, DMF, rt, 16 h, (b) NaHCO3(aq),
38–90%; (ii) 0.5 M HCl/CH3OH, rt, 4 h, 65–95%.
Scheme 4 A mechanism for the formation of bis-triazole 4.21,22
This journal is © The Royal Society of Chemistry 2017
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View Article Online(50-FAM-TATAGCTATATTTTTTTATAGCTATA-TAMRA-30), where
FAM is the uorophore donor (6-carboxyuorescein) and
TAMRA is the uorophore acceptor (6-carboxy-N,N,N0,N0-
tetramethylrhodamine).
Table 1 shows the eﬀect of three diﬀerent concentrations of
compounds 44–49, 51, 53 and the known G4 binder RHPS4 (ref.
16) (Fig. 2) on the melting temperature (DT1/2) of the labeled
oligomers F21T, c-kit2, Hsp90a and F10T, respectively.
The data show that ligands 44–49, 51 and 53 show
a moderate ability to stabilize G-quadruplexes. Though most
values are appreciably smaller than those for RHPS4, they are
still signicant in the sense that they allow us to evaluate rela-
tive aﬃnities and trends. The ligands with aminoacetyl 44–46 (n
¼ 1) are poor G-quadruplex stabilizers, the reason might be that
the short side-chains impede eﬀective positioning of the
protonated amine in the sugar-phosphate backbone loops, or
simply do not provide suﬃcient surface area for the ligand to
bind to the G-quadruplex. The morpholino ligands 45, 48, 51
and 53 showed no signicant G-quadruplex stabilization, which
might result from reduced electrostatic interactions in the
backbone and grooves by the uncharged morpholine moiety.
For example, the presence of diethylamino group (ligand 47)
and piperidino group (ligand 49) in place of morpholino group
of the inactive ligand 48, signicantly improved the biochem-
ical properties and the binding aﬃnity of 47 and 49 towards the
three types of G-quadruplexes.
The results indicated that ligands 47 and 49 induce
signicant stabilization (DT1/2 > 3.50 C) of the three types of
G-quadruplex structures at 5.0 mM concentration, with partic-
ular aﬃnity for the quadruplex formed by the Hsp90a promoterRSC Adv., 2017, 7, 47297–47308 | 47301
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Fig. 3 CD spectra of h-Tel and the complexes with ligand 47 and
RHPS4 in potassium chloride buﬀered to pH ¼ 7.0, at 25 C, (A) 3.3 mM
of h-Tel with 16.5 mM of ligand 47 and RHPS4 (of the ratio 1 : 5 of DNA
to ligand); (B) 1.0 mM of h-Tel with 15.0 mM of ligand 47 and RHPS4 (of
the ratio 1 : 15 of DNA to ligand); (C) 1.0 mM of h-Tel with 25.0 mM of
ligand 47 and RHPS4 (of the ratio 1 : 25 of DNA to ligand).
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View Article Onlinesequence. Therefore, the study reveals the ligands 47 and 49 to
be the best binders of the series towards telomeric G4-DNA, and
promoter sequences G4-DNA of c-Kit2 and Hsp90a, respectively,
over the concentration range examined. Good selectivity for G-
quadruplex DNA vs. duplex DNA was displayed by the ten
ligands over the concentration range used. None of them were
observed to signicantly increase the melting temperature of
duplex forming strand F10T (ds), suggesting a very low stability
for any duplex–ligand complex.
According to the FRET assay results, we nd that an increase
in length of the side chain by one –CH2– unit results in a large
increase in the ability of the compounds to stabilize G-
quadruplex DNA structure. Also, the nature of the amine
substituent at the terminus of the side chain greatly aﬀects the
ability of the compounds to stabilize quadruplex DNA.
In a number of cases (e.g. 47 and 49), there is a noticeable
jump in DT1/2 from 3 mM to 5 mM. One possible explanation for
this is that these ligands show cooperative binding to the DNA.
This would not be unusual for quadruplex binders – e.g. coop-
erativity in binding of RHPS4 to the c-kit DNA quadruplex has
been detected by mass spectroscopy.19
There are a few examples of negative DT1/2 values but on the
whole they are within experimental error of zero. However
a negative DT1/2 value is of course quite possible, if the ligand
stabilizes some unfolded form of the DNA more strongly than it
stabilizes the quadruplex fold.
When comparing the melting temperatures of the eight
ligands 44–49, 51 and 53 with those of the known G-quadruplex
binder RHPS4, we notice that all the new ligands are less
eﬀective at G-quadruplex stabilization. The key diﬀerence
between the bis-triazoles series 44–53 and the G4 binders
RHPS4 (ref. 16), trisubstituted acridine BRACO-19 (ref. 14) and
tetrasubstituted naphthalene diimide BMSG-SH-3 (ref. 12)
(Fig. 2) is the presence of the two sp3 methylene groups within
the aromatic region that might perturb the planarity of the
hydrophobic aromatic core, and thus aﬀect the p–p staking of
the ligands on to the terminal G-quartet. As well as the presence
of four hydrophilic arms terminating in protonated piperazine
groups and three terminating in protonated pyrrolidine in
BMSG-SH-3 and BRACO-19, respectively, increases their elec-
tronic interaction with the G4 grooves, in comparison to the bis-
triazoles 47 and 49.
2. Circular dichroism spectroscopy. Circular dichroism
spectroscopy28–30 was used to investigate the interaction of
ligand 47 with human telomeric DNA sequences and inuence
on the G-quadruplex folding topology (parallel or anti-parallel).
Parallel G-quadruplexes, where all strands are in the same
orientation, give CD spectra with a maximum at 260 nm and
a shallow dip at 240 nm. Anti-parallel quadruplexes show
a maximum ellipticity at 290 nm and a minimum at 260 nm.31
We selected ligand 47 for the rst CD study as it has the highest
aﬃnity for the telomeric G-quadruplex. Since the FRET studies
indicated a ligand : DNA ratio of at least 5 : 1 was required to
observe signicant quadruplex stabilization, stock solutions of
bis-triazole 47 and the known binder RHPS4 were added to the
22 base human telomeric G4 oligonucleotide AGGG(TTAGGG)3
(h-Tel) in potassium chloride buﬀer medium to generateThis journal is © The Royal Society of Chemistry 2017solutions of (3.3 mM) h-Tel with (16.5 mM) ligand 47 and RHPS4
of the ratio 1 : 5 of DNA to ligand, (1.0 mM) of h-Tel with (15.0
mM) of ligand 47 and RHPS4 of the ratio 1 : 15 of DNA to ligand,
and (1.0 mM) of h-Tel with (25.0 mM) of ligand 47 and RHPS4 of
the ratio 1 : 25 of DNA to ligand.
The CD spectrum (Fig. 3) of the native h-Tel (red line) shows
a strong positive band at 290 nm, with a small minimum at
235 nm and a number of additional broad positive bands
apparent at 250 nm and 275 nm. This spectrum is likely to
correspond to a mixture of parallel and anti-parallel folds
possibly including hybrid forms as well.8,19,31,32 The CD spectra
A, B and C show that the G-quadruplex topology of h-Tel is
retained on binding to ligand 47, with minor changes in the
spectra (green line) being apparent, indicating that 47 does notRSC Adv., 2017, 7, 47297–47308 | 47303
Fig. 4 Top views in VMD visualizing software of: (A) 30-side template
of the telomeric parallel G4-DNA; (B) the common pose for ligands
44–53 with the 30-side of G4-DNA.
Fig. 5 A side view of ligand 47with the 30-side G4 template (hydrogen
bonds in yellow lines).
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View Article Onlineinduce major changes in telomeric topology on binding. In
contrast, binding of RHPS4 (blue line) induces major changes
in the CD spectra that are interpreted as almost complete
conversion to the anti-parallel-stranded topology. These results
suggest that, compared to RHPS4, 47 is a relatively promiscuous
G-quadruplex ligand, and/or that CD spectroscopy is not
sensitive enough to clearly resolve the topological dependence
in the relatively weak binding aﬃnity of ligand 47 – compared to
RHPS4 – towards the human telomeric G4 structure, (shown by
the FRET melting assay). Because ligand 47, our best telomeric
G4 stabilizer, proved not to have a detectable inuence on the
topology of the quadruplex (parallel versus antiparallel form),
we did not consider it of value to investigate other, structurally
related but lower aﬃnity, ligands such as 49.
3. Molecular modeling. In order to gain insight into the
nature of the ligand–DNA interactions, and help rationalize the
FRET melting data, a series of molecular modeling studies was
performed. The synthesized bis-triazoles 44–53 were docked to
the human telomeric parallel stranded (propeller-like) G-
quadruplex DNA crystal structure (PDB ID 1KF1),8 at both 30-
and 50-sides, using the Glide soware package.33,34 We used the
parallel structure as a template for modeling studies rather than
any of the anti-parallel forms obtained from NMR studies
because of the relatively inconclusive FRET data, the fact that its
topology is such that guanine tetrads at both 30- and 50-sides are
potential binding sites for ligands,35 and in addition because
the parallel structure is considered to be biologically more
relevant due to the higher intracellular concentration of K+.8,31
Furthermore, the structures of the synthesized bis-triazoles 44–
53 are quite similar to that of the known binder TRZ which
stabilizes the parallel human G4 structure selectively.19
In analysing the docking data, we concentrated on high-
scoring poses that were conserved across all members of the
congeneric set of ligands, in order to investigate and explore the
binding interactions between the ligands and G4-DNA.
The study showed that all the ligands should have aﬃnity for
both 30- and 50-faces of the human telomeric parallel standard
G-quadruplex DNA structure. Fig. 4 shows the VMD top views of
the 30-face of the telomeric parallel G-quadruplex DNA template,
and the set of ligands 44–53 bound to the 30-side of G4-DNA in
the best pose for their common core. Despite diﬀerences in the
sidechains, the majority of the ligands bound in a very similar
fashion with only minor variations in some intermolecular
interactions between models. Furthermore, all the ligands were
oriented and posed with the 30-face in fashions that agree with
the accepted requirements for the stabilization of G-quadruplex
structures; the ligands' hydrophobic aromatic cores are posi-
tioned over the external G-quartet and their hydrophilic amino
side arms are directed into the grooves and TTA loops of the
telomeric G4-DNA, as shown in the VMD top views (Fig. 4B).
In order to gain insight into the nature of interactions between
synthesized bis-triazoles 44–53 and the 30-side of the telomeric
parallel G-quadruplex, the side view of the common pose for
ligand 47 (the best binder of the series) with 30-face was studied
closely. The side view in VMD (Fig. 5) shows that the aromatic
core of ligand 47 does not stack perfectly over the external
guanine tetrad, resulting in weak p–p interactions between the47304 | RSC Adv., 2017, 7, 47297–47308two. This explains and rationalizes the moderate binding aﬃnity
the ligands revealed by the FRET melting data (DT1/2). The main
reason for this ineﬀective stacking is the presence of the two sp3
methylene groups within the aromatic region which perturb the
planarity of the hydrophobic aromatic core. The side view also
shows the amide nitrogen and the tertiary amine functionality at
the ends of the side chains both contribute towards stabilization
of the complex by forming hydrogen bonds to phosphate groups
of one groove and two TTA loops. Furthermore, the presence of
a positive charge on the protonated tertiary amino group would
enhance the electrostatic interactions with the negatively charged
phosphate groups in the loops.
Similar results were obtained from docking the bis-triazoles
44–53 to the 50-side of G4-DNA template: a high-scoring
“consensus” pose is found in which the benzoquinone core
stacks appreciably, but sub-optimally, with the G-quadruplex face
and the side chains orient to nd favourable electrostatic binding
opportunities in the sugar–phosphate grooves and loops.This journal is © The Royal Society of Chemistry 2017
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View Article Online4. Cell biology studies. The anti-proliferative activities of the
eight bis-triazoles 44–53 plus the known G-quadruplex binder
RHPS4 (ref. 16) were evaluated in vitro using the MTT assay36,37
against human carcinoma HCT-116 (colorectal) and MiaPaCa-2
(pancreatic) cell lines, and also human MRC-5 (embryonic lung
broblasts) to investigate their selective cytotoxicity. Colorectal
carcinoma is the third most common cancer and caused more
than 600 000 deaths globally in 2008.38 Pancreatic carcinoma is
particularly resistant to chemotherapy, oen diagnosed with
metastatic disease and has an appalling ve year survival rate
(<5%).39 Thus, the development of new therapies for such
malignant diseases represents a current unmet medical need.
Concentrations at which cell growth is inhibited by 50%
(GI50) aer 72 h exposure of cells to bis-triazoles 44–53 and
RHPS4 were calculated from dose–response curves and are
presented in Table 2. RHPS4 structure is shown in Fig. 2.
As can be seen from Table 2, most of the compounds 44–49,
51, 53 and RHPS4 show potent cellular growth inhibitory
activity against both carcinoma cell lines in the concentration
range (0.01–100 mM) used. The highest potency against humanTable 2 Growth inhibitory activity of compounds 44–49, 51, 53 and RHP
cell lines. GI50 values are represented as mean  standard error of mea
yellow highlights represent themost potent ligands against the three type
in the literature RHPS4
This journal is © The Royal Society of Chemistry 2017cancer cell lines is shown by the ligand 44 (a non G4 binder)
with GI50 values of 70 nM for HCT-116 and 60 nM for MiaPaCa-
2, ligand 46 (a non G4 binder) which has a GI50 value of 70 nM
for HCT-116, and our best c-Kit2 and Hsp90a G4 binder 49
which shows GI50 values of 80 nM for HCT-116 and 60 nM for
MiaPaCa-2. The three compounds show almost identical
activity with uniform growth inhibitory responses by the two
cancer cell lines HCT-116 and MiaPaCa-2 (except 46). We see
that ligand 47, the potent telomeric G4 stabilizer, has relatively
lower anti-proliferative activity against both human cancer cell
lines. This strongly suggests that the synthesized bis-triazoles
44–49, 51, 53 perturb molecular targets other than the telo-
mere, and mechanisms of action in addition to G-quadruplex
binding may contribute to antitumour activity.
The results show that the eight synthesized ligands have higher
potencies against the human cancer cell lines HCT-116 and
MiaPaCa-2 than in normal human lung MRC-5 broblasts, infer-
ring good selectivity in their cellular growth inhibitory activity for
human cancer cells over human normal cells. These results
suggest 44–53 have promise as new therapeutic anticancer agents.S4 against human cancer HCT-116 and MiaPaCa-2 and normal MRC-5
n (SEM) of at least two independent experiments (n ¼ 8 per trial). The
s of cell lines, while the green highlight represents the knownG4 binder
RSC Adv., 2017, 7, 47297–47308 | 47305
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View Article OnlineIn particular, the results indicate that compound 49 is >16-
fold more active against cancer human cell lines HCT-116 and
MiaPaCa-2 than against normal human MRC-5 cells. Compared
to RHPS4, 49 is both more potent against the two tumour cell
lines (GI50 values # 0.08 mM) and more selective for them over
MRC-5.
Conclusions
In conclusion, the design, synthesis, biophysical and biological
evaluation of a new series of bis-triazoles 44–53 as potential G-
quadruplex stabilizers have been described. The target ligands
can be obtained through an eﬃcient, convergent, synthetic route
in moderate to good yields. In FRET assays two ligands show
signicant binding to the three types of G-quadruplex structures
with selectivity towards the promoter sequence of the Hsp90a
oncogene. The synthesized bis-triazoles 44–49, 51 and 53 are
selective towards G4-DNA vs. duplex-DNA. The planarity of the
aromatic core, number of the hydrophilic side arms and the
nature of the amino group at their termini greatly aﬀect the
ability of the compounds to stabilize the G-quadruplex. Circular
dichroism-based studies of the topology of the human telomeric
G-quadruplex obtained from its interaction with ligand 47
suggest that both parallel and anti-parallel folds might be
present. In MTT assays, most of the synthesized ligands show
potent cell growth inhibitory activity against human carcinoma
(colon and pancreatic) cell lines. Notably they are more potent
towards human cancer cells than embryonic lung broblasts.
The weak correlation between FRET and MTT assay results
suggests that the synthesized ligands may have additional
mechanisms of action besides targeting G-quadruplexes.
Docking studies give us a clear idea about the nature of the
ligand–quadruplex DNA interactions and rationalize the
moderate binding aﬃnity the ligands show in the FRET experi-
ments, suggesting that the hydrophobic core is not planar enough
for optimal p–p stacking interactions between the aromatic
portion of the ligands and the external G-quartet. This informa-
tion can guide the optimization of ligands 44–53, for increased
binding aﬃnity and selectivity toward G-quadruplex structures.
Experimental section
FRET analysis
All oligonucleotides and their uorescent conjugates were
purchased from Sigma. DNA was initially dissolved as a stock
100 mM solutions in puried water; further dilutions were
carried out in the relevant buﬀer. The ability of the compounds
to stabilize G-quadruplex DNA was investigated using a uo-
rescence resonance energy transfer (FRET) assay modied to be
used as a high-throughput screen in a 96-well format. The dual
labeled oligonucleotides F21T (50-FAM-GGGTTAGGGT
TAGGGTTAGGG-TAMRA-30), c-kit2 (50-FAM-CCCGGGCGG
GCGCGAGGGAGGGGAGG-TAMRA-30) and Hsp90a (50-FAM-
GGGCCAAAGGGAAGGGGTGGG-TAMRA-30); donor uorophore
FAM: 6-carboxyuorescein; acceptor uorophore TAMRA: 6-car-
boxy-N,N,N0,N0-tetramethylrhodamine used as the FRET probes,
were diluted from stock to the correct concentration (0.2 mM) in47306 | RSC Adv., 2017, 7, 47297–47308a 60 mM potassium cacodylate buﬀer (pH 7.4) and then
annealed by heating to 95 C for 10 min, followed by cooling to
room temperature in the heating block for 3.5 h. An analogous
protocol was used in the preparation of the labeled hairpin DNA
for experiments assessing the duplex-stabilizing interactions of
the compound. The oligonucleotide used (F10T) was purchased
as the dual-labeled probe forming the palindromic decamer
sequence d(TATAGCTATA) with T6 between two sequences to
make the hairpin loop (50-FAM-TATAGCTATATTTTTTTA
TAGCTATA-TAMRA-30) and annealed under the same condi-
tions as the other oligonucleotides. Compounds were stored at
20 C as 1 mM stock solutions in amixture of hydrochloric acid
(75% 1 mMHCl and 25% puried water) and DMSO (9 : 1), aer
which 60 mM potassium cacodylate buﬀer (pH 7.4) was used in
all subsequent steps. All experimental values were determined in
triplicate. 96-well polypropylene plates (Agilent Technologies)
were prepared by aliquoting 50 mL of the annealed DNA into each
well, followed by 50 mL of compound solutions.1,25Measurements
weremade on a real-time PCR apparatus40 (MX3005P, Stratagene)
with excitation at 450–495 nm and detection at 515–545 nm.
Fluorescence readings were taken at intervals of 0.5 C over the
range 25–99 C for 148 cycles, with a constant temperature being
maintained for three minutes at 25 C and 30 seconds prior to
each reading to ensure a stable value. Final analysis of the data
was carried out using a Microso Excel 2010. Esds in DT1/2 are
4.0 C. In brief, for the determination of the melting temper-
ature, the raw data from the uorescence detector was analysed
by two ways: (i) normalizing the uorescein emission between
0 and 1, then calculating the temperature for which the
normalized emission equals to 0.5 which is dened as T1/2, and
the normalized melting curve was plotted as normalized uo-
rescein emission vs. compound concentration; (ii) the uorescein
emission data were rst smoothed using 8-point running
average, subsequently the rst derivative of the smoothed data
was calculated, then the temperature that matches themaximum
of the rst derivative is determined which is dened as Tmax. The
rst derivative melting curve was plotted as d(uorescein emis-
sion)/dT vs. compound concentration.26CD spectroscopy
CD and UV spectra of h-Tel oligonucleotides were recorded on
an Applied Photophysics Chirascan plus spectrophotometer
interfaced with Chirascan soware. The optical system con-
sisted of a 150 W ozone producing xenon lamp, circular light
polarizer and end-mounted photomultiplier. Temperature
regulation was performed using a Poly Science water bath and
Quantum Northwest TC125 controller. Calibration was per-
formed prior to these experiments with D-camphorsulfonic acid.
Data were recorded in a 1 cm path length quartz cuvette con-
taining 3 mL samples. Bandwidth was set to 1.0 nm for entrance
and exit, and data was recorded with steps of 1 nm over the
wavelength range 340–215 nm. The number of samples was set
to 100 000 for CD and 10 000 for UV with adaptive sampling
enabled. Each reported curve is the average of 3 repeat scans.
The oligonucleotide 50-AGGGTTAGGGTTAGGGTTAGGG-30
(h-Tel) was supplied lyophilized and puried by desalting byThis journal is © The Royal Society of Chemistry 2017
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View Article OnlineSigma. Dilution of the lyophilized sample was performed using
100 mM potassium chloride and 10 mM potassium phosphate
buﬀer solution at pH 7.0. The concentration of DNA stock
solution was determined using molar extinction coeﬃcient
228 500 mol1 cm1 at a UV maximum of 260 nm. Compounds
to be tested for interaction with h-Tel were dissolved in meth-
anol to make a 2.0 mM solution. Solutions of 1.0 and 3.3 mM
h-Tel in potassium chloride buﬀer were annealed by heating to
95 C for 10 minutes before being allowed to slowly cool to
ambient temperature over 4 hours, with or without the addition
of a ligand at ratios of 1 : 5, 1 : 15 and 1 : 25 DNA to ligand
concentration. Analysis of data was performed using Microso
Excel. Baseline data was collected using buﬀer solution in the
same cuvette and subtracted from sample spectra, aer which
the data was normalized to zero at 340 nm.28,41MTT assay
The antiproliferative activity of experimental agents was evalu-
ated by MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazo-
lium bromide] assay36 on 3 diﬀerent human cell lines: colon
(HCT-116) and pancreatic (MiaPaCa-2) carcinoma, and embry-
onic lung broblasts (MRC-5). Cell lines were sourced from the
American Type Culture Collection (ATCC) and stored in liquid
nitrogen. Low passage numbers (#20) were used in all experi-
ments. Lonza MycoAlert™mycoplasma detection kits were used
(according to manufacturer's instructions) ensuring cultures
were contamination-free. The carcinoma cell lines were main-
tained in RPMI-1640 (Sigma-Aldrich (UK), CN: R8758) medium
supplemented with 10% (v/v) heat-inactivated fetal bovine serum
(FBS). MRC-5 broblasts were maintained in Minimum Essen-
tial Medium (MEM) Eagle (Sigma-Aldrich (UK), CN: M0275)
supplemented with 10% (v/v) FBS, 1% sodium carbonate (7.5%),
1% non-essential amino acids (0.1 mM), 1% HEPES (1 M), 1% L-
glutamate (200 mM) and 1% penicillin. The cells were seeded
into 96-well plates at density of 3 103 per well (180 mL per well)
and allowed to adhere for 24 h at 37 C/5% CO2. Agent top stock
solutions (10 mM in DMSO) were then freshly made. Serial
dilutions were prepared in the same media as mentioned above
for addition to carcinoma and normal cells. Control wells
received vehicle alone (20 mL per well). Final test agent concen-
trations in the wells were; 0.01, 0.05, 0.1, 0.5, 1, 5, 10, 50 and 100
mM. The nal concentration of DMSO in the wells never excee-
ded 1%. Vehicle control assays were performed (0.0001–1%
DMSO). Experimental plates were incubated for a further 72 h
period at 37 C/5%CO2. Cell viability was recorded at the time of
agent addition (T0) and aer 72 h exposure: following addition of
MTT solution (2 mg mL1 in PBS: 50 mL per well), experimental
plates were incubated for 3 h to allow reduction of MTT by viable
cells to insoluble dark purple formazan crystals. The superna-
tant in each well was then aspirated, and cellular formazan was
solubilized by addition of DMSO (150 mL per well). Absorbance
was read at a wavelength of 550 nm by using an Anthos Labtec
systems plate reader. The measured intensity is proportional to
metabolic activity, which correlates with viable cell numbers.
Estimated GI50 values (test agent concentrations that inhibit cell
growth by 50%) were calculated.39This journal is © The Royal Society of Chemistry 2017Molecular docking studies
1. Preparation of DNA and ligands. The crystal structure of
the 22-mer parallel-standard propeller-loop topology (PDB
1KF1: resolution 2.10 A˚) human telomeric G-quadruplex8,35 was
obtained from the Protein Data Bank and used as a starting
point to examine plausible interactions with the ligands. Using
the Maestro programme (in Schrodinger package), the terminal
50 adenine residue was removed to generate 21-mer structure, so
the at planar quartet is exposed to the ligand. Using “Protein
Preparation” tools in Glide soware34 (built in Maestro), water
molecules were removed from the structure le, missing
hydrogen atoms were added, non-polar hydrogens merged to
their corresponding carbons, bond orders were assigned and
potassium ions were deleted because we expect their eﬀect to be
almost independent of the ligand, and so not contributing to
selectivity. The molecular models for the bis-triazoles series of
ligands were constructed, minimized, partial charges were
calculated, atomic names and bond orders were assigned using
Maestro program.
2. Receptor grid generation and docking protocol. The
receptor grid map representing G-quadruplex DNA was calcu-
lated and generated using “Glide Generation” option in
“Docking” tools of Glide soware. The grid was chosen to
encompass the entire DNA molecule, such that it ts to docked
ligands with length of #36 A˚. The size of the entire green
small box around the external G-quartet of the G4-DNA is 14 A˚ 
14 A˚  14 A˚.
The automated docking studies were carried out using
“Glide docking” tools of Glide soware, which uses the Chem-
Score function of Eldridge et al.42 to calculate Glide docking
scores. The programme ran 10 000 docking trials per ligand,
and wrote out at most 50 poses for each ligand.
Chemistry
Details of all synthetic procedures are included in the ESI.†
PDB ID code
The PDB ID code for the published telomeric parallel G-
quadruplex DNA structure is 1KF1.
Conﬂicts of interest
There are no conicts to declare.
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c-Kit2 Labelled G-quadruplex forming oligomer of the
promoter sequence c-kit2 oncogene
FAM 6-(Carboxyluorescein)
FRET Fluorescence resonance energy transfer
F10T Hairpin double helix forming labeled oligomer
F21T Labeled G-quadruplex forming oligomer of human
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View Article OnlineGI5047308 | RSCConcentration inhibiting 50% cell growth
Glide Grid-based ligand docking with energetic
HCT-116 Human colorectal carcinoma cell line
Hsp90a Labeled G-quadruplex forming oligomer of the
promoter sequence Hsp90a oncogene
MiaPaCa-
2Human pancreatic carcinoma cell line;
MRC-15 embryonic lung broblast cell lineMTT 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl
tetrazolium bromideOD Optical density
TAMRA 6-Carboxytetramethylrhodamine
VMD Visual molecular dynamicsAcknowledgements
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